BioCryst falls on HAE miss for avoralstat

BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) crumbled $4.36 (71%) to $1.78 on Monday after its oral avoralstat ( BCX4161) missed the primary endpoint in the Phase II/III OPuS-2 trial to prevent acute attacks in patients with hereditary angioedema (HAE). Avoralstat failed to significantly reduce angioedema attack frequency vs. placebo. Patients in the double-blind trial received 300 or 500 mg avoralstat thrice daily or placebo for 12 weeks.

The company said high-dose avoralstat showed significant improvements vs. placebo on the secondary endpoints of duration of attacks and Angioedema Quality of Life total score. ...